Abstract:Introduction: The complexity of Inflammatory Bowel Diseases (IBD) presents challenges for the management of these diseases. Predicting treatment outcomes remains difficult, leading to suboptimal outcomes and high costs. Emerging evidence suggests the potential of the gut microbiome in predicting response to biologic treatments. In this prospective study we aimed to predict treatment response to vedolizumab and ustekinumab in 79 IBD patients by integrating clinical data, gut microbiome profiles and fecal metabolites and validating these findings in a replication cohort of 47 IBD patients. Methods: Treatment response was defined as either continuation or discontinuation of the biologic at six months. We performed whole genome metagenomic shotgun sequencing on the baseline fecal samples to detect microbial and functional profiles. Additionally, over 1000 metabolites were captured through untargeted metabolomic profiling. Baseline diversity, dissimilarity and differential abundance analyses compared responder and non-responder groups. The prediction tool CoDaCoRe was used to identify predictive log-ratio biomarkers. We tested our identified ratios in an external cohort and attempted to replicate the microbiome-based signals of previous studies. Finally, we used a neural-network framework to model the relationship between metabolites and microbes, comparing these clusters in responders and non-responders and tested our approach with different definitions of response. Results: We identified seven metabolites to be differentially abundant between responders and non-responders (FDR < 0.05). However, no significant differences in bacterial species and pathways were detected at baseline between responders and non-responders. Our prediction analysis indicated only marginal predictive utility of the gut microbiome and fecal metabolites for treatment response, when compared to a clinical model using fecal calprotectin, disease duration and disease activity, among other factors (AUC only clinical features: 0.71±0.13, AUC microbial and clinical features: 0.73±0.12). The main predictive features of these models were the disease activity and previous anti-TNF use combined with high abundance of Phocaeicola vulgatus, Bacteroides uniformis and Alistipes onderdonkii, and the low abundance of Ruminococcus gnavus and Faecalibacterium prausnitzii. Testing our identified ratio of 10 species in an external cohort of 47 IBD patients reinforced the lack of predictive power of the microbiome. No replication of previously published predictive signals of the microbiome was observed. Additionally, we identified 2 metabolite clusters and 1 microbiome cluster associated with response, and observed that predictors were highly dependent on the definition of response. Conclusion: While previous studies of similar size have shown that microbial features can predict response to either vedolizumab (VedoNet), or vedolizumab, ustekinumab and anti-TNF, our comprehensive study found no significant differences in the gut microbiome at baseline between responders and non-responders among IBD patients treated with ustekinumab or vedolizumab. Microbial features added no predictive power to drug response in our IBD patient cohort or an independent replication cohort. Addition of metabolite features did not improve predictive power. These findings suggest minimal impact of the pre-treatment gut microbiome on treatment outcomes with these medications in IBD patients with long term chronic disease. Generalizability beyond initial study cohorts is limited, leaving predictors for individualized IBD-medication selection unidentified, but based on this work, likely do not lie in the fecal microbiome.

P206 Metabolomic predictors of response to vedolizumab in Inflammatory Bowel Disease

P640 Role of vedolizumab trough levels in predicting clinical response in Inflammatory Bowel Disease: a multicentre prospective study

Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease

P041 Assessment of Serum Biomarkers associated with Vedolizumab Therapy Response in Inflammatory Bowel Disease

A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease

OP05 High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitis

VEDOLIZUMAB RESPONSE AND NON-RESPONSE IN ULCERATIVE COLITIS: INSIGHTS FROM SPATIAL TRANSCRIPTOMICS

P509 Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn’s disease

P033 Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment

DOP22 Predictive biomarkers of therapeutic response in Inflammatory Bowel Disease: a step towards personalized medicine

P838 Determing factors that influence Vedolizumab Response in Inflammatory Bowel Diseases: A Prospective Study

P502 Multimodal profiling of peripheral blood identifies proliferating circulating effector CD4 T cells as predictors for response to integrin alpha4 beta7-blocking therapy in patients with Inflammatory Bowel Disease

P063 Interleukin-8 mucosal transcript as predictor of response to Vedolizumab treatment in Ulcerative Colitis: preliminary results from a prospective study

Therapeutic Drug Monitoring as a Tool for the Clinical Outcome Prediction in Vedolizumab-Treated Patients: An Italian Pilot Study

Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review

P266 Predictive tissue-based biomarkers in treatment of Inflammatory Bowel Disease with biologicals and small molecules: a systematic review

Deciphering Microbial Composition in Patients with Inflammatory Bowel Disease: Implications for Therapeutic Response to Biologic Agents

P803 iGenoMed-MTT: A prospective multiomic study of response to molecularly targeted therapies in IBD

Predictors of the efficacy of vedolizumab in patients with ulcerative colitis

OP40 Transcriptomic signature of response to vedolizumab in patients with moderate-to-severe ulcerative colitis: Results from an international, multicentre, retrospective cohort study